Back to Search
Start Over
Nephrotic syndrome due to primary systemic AL amyloidosis, successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone.
- Source :
-
Internal medicine (Tokyo, Japan) [Intern Med] 2008; Vol. 47 (6), pp. 543-9. Date of Electronic Publication: 2008 Mar 17. - Publication Year :
- 2008
-
Abstract
- We report 3 patients with nephrotic syndrome ascribed to primary systemic AL amyloidosis that were successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone. M-protein in serum disappeared soon after VAD, and nephrotic syndrome gradually improved in parallel with a decrease in daily protein excretion in urine. Long-term follow-up of these patients showed neither relapse of nephrotic syndrome nor reappearance of M-protein. High-dose melphalan followed by autologous stem cell support is a standard therapy for primary systemic AL amyloidosis, but in high-risk cases for this treatment, such as elderly patients and those with multiple organ involvement, VAD might be a therapeutic option.
- Subjects :
- Aged
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Dexamethasone administration & dosage
Doxorubicin administration & dosage
Female
Humans
Male
Middle Aged
Nephrotic Syndrome diagnosis
Vincristine administration & dosage
Amyloidosis complications
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Nephrotic Syndrome drug therapy
Nephrotic Syndrome etiology
Subjects
Details
- Language :
- English
- ISSN :
- 1349-7235
- Volume :
- 47
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Internal medicine (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 18344643
- Full Text :
- https://doi.org/10.2169/internalmedicine.47.0709